PRAVALIP 10

Riik: Iisrael

keel: inglise

Allikas: Ministry of Health

Osta kohe

Infovoldik Infovoldik (PIL)
16-08-2020
Avaliku hindamisaruande Avaliku hindamisaruande (PAR)
18-08-2016

Toimeaine:

PRAVASTATIN SODIUM

Saadav alates:

UNIPHARM LTD, ISRAEL

ATC kood:

C10AA03

Ravimvorm:

TABLETS

Koostis:

PRAVASTATIN SODIUM 10 MG

Manustamisviis:

PER OS

Retsepti tüüp:

Required

Valmistatud:

TRIMA ISRAEL PHARMACEUTICAL PRODUCTS MAABAROT LTD, ISRAEL

Terapeutiline rühm:

PRAVASTATIN

Terapeutiline ala:

PRAVASTATIN

Näidustused:

Pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . Pravastatin should be used in addition to a diet and other nonpharmacological measures alone has been inadequate. Primary prevention of coronary events: In hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) Reduce the risk of myocardial infarcton. 2) Reduce the risk for revascularization. 3) Reduce the risk of deaths due to cardiovascular causes with no increase in death non-cardiovascular causes. Secondary prevention of cardiovascular events: a) Atherosclerosis: In hypercholesterolemic patients with clinically evident coronary artery disease including prior MI pravastatin is indicated to: 1)Slow the progression of coronary atherosclerosis. 2) Reduce the risk of acute coronary events. b) Myocardial infarction: in patients with previous

Loa andmise kuupäev:

2010-03-31

Infovoldik

                                PATIENT PACKAGE INSERT IN
ACCORDANCE WITH THE PHARMACISTS’
REGULATIONS )PREPARATIONS( – 1986
The medicine is dispensed
with a doctor’s prescription only
PRAVALIP 10; 20; 40
TABLETS
COMPOSITION:
Each PRAVALIP 10 tablet contains:
Pravastatin sodium 10 mg
Each PRAVALIP 20 tablet contains:
Pravastatin sodium 20 mg
Each PRAVALIP 40 tablet contains:
Pravastatin sodium 40 mg
For the list of inactive ingredients, please see
section 6.
READ THIS LEAFLET CAREFULLY IN ITS ENTIRETY
BEFORE USING THE MEDICINE. This leaflet
contains concise information about the
medicine. If you have further questions, refer
to the doctor or pharmacist.
This medicine has been prescribed to treat
your ailment. Do not pass it on to others. It
may harm them, even if it seems to you that
their ailment is similar.
This medicine is not intended for use in
children and adolescents under 18 years of
age.
THERAPEUTIC GROUP: Pravastatin belongs to
a group of medicines called “statins”. Statins
inhibit the activity of the HMG-CoA reductase
enzyme.
1. WHAT IS THE MEDICINE INTENDED FOR?
Reduction
of
cholesterol,
LDL-C
and
triglyceride levels, and increase in HDL-C
levels. In hypercholesterolemic patients
and with no evidence of coronary disease,
pravastatin reduces the risk of myocardial
infarction and extends the life expectancy.
In
patients
with
atherosclerosis
and
average )normal( or high cholesterol level,
pravastatin reduces the risk of overall mortality
and of mortality due to heart diseases,
and reduces the risk of heart attack; in
hypercholesterolemic patients, pravastatin
reduces the risk of angina pectoris.
2. BEFORE USING THE MEDICINE
DO NOT USE THE PREPARATION IF:
• you are pregnant, planning to become
pregnant or are breastfeeding.
• you are sensitive )allergic( to pravastatin
or to any of the additional ingredients
contained in the medicine )listed in section
6(.
• you are suffering from active liver disease
or from unexplained, persistent elevations
in liver function test results.
119108010
03D20
SPECIAL WARNINGS REGARDING USE
                                
                                Lugege kogu dokumenti
                                
                            

Dokumendid teistes keeltes

Infovoldik Infovoldik araabia 16-08-2020
Infovoldik Infovoldik heebrea 05-08-2020

Otsige selle tootega seotud teateid

Vaadake dokumentide ajalugu